Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Inclusion criteria: * Diagnosis of type 2 diabetes mellitus prior to informed consent * Male and female patients on diet and exercise regimen for 12 weeks prior to informed consent who are: * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or, * pre-treated with one oral antidiabetic drug (except sulfonylurea and thiazolidinedione); the present antidiabetic therapy has to be unchanged for at least 12 weeks prior to the informed consent. (Sulfonylurea is permitted as pre-treatment drug only if the dose is equal or less than a half of daily maximum approval dose.) * Glycosylated haemoglobin (HbA1c) at Visit 1 (screening) * for patients without antidiabetic therapy : HbA1c \>=7.0 to =\<10.0% * for patients with one oral antidiabetic drug : HbA1c \>=7.0 to =\<9.5% Exclusion criteria: * Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L) * Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 (moderate and severe renal impairment, modification of diet in renal disease (MDRD) formula) * Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent * Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)